Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients

Neoplasma

Volumn 59, Issue 4, 2012, Pages 376-383

  Rako, I ^a   Jakic Razumovic, J ^a   Katalinic, D ^a   Sertic, J ^a   Plestina, S ^a  

^a KBC Zagreb   (Croatia)

Author keywords

BRAF; Colorectal cancer; KRAS

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; FEMALE; FLUORESCENCE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; ADOLESCENT; CANCER GRADING; CANCER STAGING; COLORECTAL TUMOR; CROATIA; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CROATIA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84864542760     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_049     Document Type: Article

References (39)

1. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J et al. Cancer statistics, 2007 CA. A Cancer Journal for Clinicians 2007; 57: 43-66. http://dx.doi.org/10.3322/canjclin.57.1.43
2. FEARON ER, VOGELSTEIN B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67. http://dx.doi.org/10.1016/0092-8674(90)90186-I
3. JONES S, CHEN W, PARMIGIANI G, DIEHL F, BEERENWINKEL N et al. Comparative lesion sequencing provides insights into tumor evolution. PNAS 2008; 105; 11; 4283-8. http://dx.doi.org/10.1073/pnas.0712345105
4. DAVIES H, BIGNELL GR, COX C, STEPHENS P, EDKINS S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417; 949-954. http://dx.doi.org/10.1038/nature00766
5. RUSSO A, BAZAN V, AGNESE V, RODOLICO V, GEBBIA N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Annals of Oncology 2005; 16 iv44-iv49. http://dx.doi.org/10.1093/annonc/mdi907
6. GATTENLOHNER S, ETSCHMANN B, KUNZMANN V, THALHEIMER A, HACK M et al. Concordance of KRAS/ BRAF mutation status in metastatic colorectal cancer before and after Anti-EGFR Therapy. J Oncol 2009; Article ID 831626; 5.
7. MONZON FA, OGINO S, HAMMOND ME, HALLING KC, BLOOM KJ et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Patol Lab Med 2009; 133; 1600-06.
8. POREBSKA I, HARLOZINSKA A, BOJAROWSKI T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21: 105-15. http://dx.doi.org/10.1159/000030116
9. REYNOLDS NA, WAGSTAFF AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004; 64: 109-118.
10. SIENA S, BIANCHI AS, NICOLANTONIO FD, BALFOUR J, BARDELLI A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. JNCI 2009; 101: 1308-24. http://dx.doi.org/10.1093/jnci/djp280
11. SALTZ LB, MEROPOL NJ, LOEHRER PJ SR, NEEDLE MN, KOPIT J et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8. http://dx.doi.org/10.1200/JCO.2004.10.182
12. JONKER DJ, O'CALLAGHAN CJ, KARAPETIS CS, ZALCBERG JR, TU D et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8. http://dx.doi.org/10.1056/NEJMoa071834
13. VAN CUTSEM E, PEETERS M, SIENA S, HUMBLET Y, HENDLISZ A et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64. http://dx.doi.org/10.1200/JCO.2006.08.1620
14. BENVENUTI S, SARTORE-BIANCHI A, DI NICOLANTONIO F, ZANON C, MORONI M et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8. http://dx.doi.org/10.1158/0008-5472.CAN-06-4158
15. ANDREYEV HJ, NORMAN AR, CUNNINGHAM D, OATES J, DIX BR et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-96.
16. SAMOWITZ WS, CURTIN K, SCHAFFER D, ROBERTSON M, LEPPERT M et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
17. EDKINS S, O'MEARA S, PARKER A, STEVENS C, REIS M et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5: 928-32. http://dx.doi.org/10.4161/cbt.5.8.3251
18. OLIVEIRA C, WESTRA JL, ARANGO D, OLLIKAINENE M, DOMINGO E et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics 2004; 13: 2303-11. http://dx.doi.org/10.1093/hmg/ddh238
19. RISIO M, MALACARNE D, GIARETTI W. Letter to the Editor. KRAS transitions and villous growth in colorectal adenomas. Cell Oncol 2005; 27: 363-6.
20. DI NICOLANTONIO F, MARTINI M, MOLINARI F, SARTORE-BIANCHI A, ARENA S et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. JCO 2008; 26: 5705-12. http://dx.doi.org/10.1200/JCO.2008.18.0786
21. AL-MULLA F, MACKENZIE EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 2001; 195: 549-56. http://dx.doi.org/10.1002/path.995
22. KOSAKA T, YATABE Y, ENDOH H, KUWANO H, TAKAHASHI T et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23. http://dx.doi.org/10.1158/0008-5472.CAN-04-2818
23. AL-MULLA F, GOING JJ, SOWDEN ET, WINTER A, PICKFORD IR et al. Heterogeneity of mutant versus wildtype in primary and metastatic colorectal carcinomas and association of codon 12 valine with early mortality. J Pathol 1998; 185: 130-8. http://dx.doi.org/10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M
24. STENSON PD, BALL EV, MORT M, PHILLIPS AD, SHIEL JA et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21: 577-581. http://dx.doi.org/10.1002/humu.10212
25. RYDBERG B, LINDAHL T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-Lmethionin is a potentially mutagenic reaction. EMBO J 1982; 1: 211-6.
26. LIJINSKY W. N-Nitroso compounds in the diet. Mutat Res 1999; 443: 129-138.
27. COLE DN, CARLSON JA, WILSON VL. Human Germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies. Environ Mol Mutagen 2008; 49: 417-25. http://dx.doi.org/10.1002/em.20390
28. GEIDO E, SCIUTTO A, RUBAGOTTI A, OLIANI C, MONACO R, RISIO M et al. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. Cytometry 2002; 50: 216-24. http://dx.doi.org/10.1002/cyto.10109
29. ANDREYEV HJ, NORMAN AR, CUNNINGHAM D, OATES JR, CLARKE PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 1998; 90: 675-84.
30. UROSEVIC N, KRTOLICA K, SKARO-MILIC A, KNEZEVIC-USAJ S, DUJIC A. Prevalence of G-to-T transversions among K-ras mutations in colorectal tumors in Yugoslavia. Int J Cancer 1993; 54: 249-54. http://dx.doi.org/10.1002/ijc.2910540215
31. COMPTON CC, FIELDING P, BUGART LJ, CONLEY B, COOPER HS et al. Prognostic factors in colorectal cancer. Arch Patol Lab Med 2000; 124: 979-93.
32. WALTHER A, JOHNSTONE E, SWANTON C, MIDGLEY R, TOMLINSON I et al. Genetic prognostic and predictive markers in colorectal cancer. Nature 2009; 9: 489-98.
33. ANWAR S, FRAYLING IM, SCOTT NA, CARLSON GL. Systematic review of genetic influences on the prognosis of colorectal cancer. British Journal of Surgery 2004; 91: 1275-91. http://dx.doi.org/10.1002/bjs.4737
34. TOL J, NAGTEGAAL ID, PUNT CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99. http://dx.doi.org/10.1056/NEJMc0904160
35. FRANKLIN WA, HANEY J, SUGITA M, BEMIS L, JIMENO A et al. Comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43-50.
36. ALLEGRA CJ, JESSUP JM, SOMERFIELD MR, HAMILTON SR, HAMMOND EH et al. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to Anti-Epidermal Growth Factor Receptor Momoclonal Antibody Therapy. J Clin Oncol 2009; 27: 2091-6. http://dx.doi.org/10.1200/JCO.2009.21.9170
37. MAESTRO ML, VIDAURRETA M, SANZ-CASLA MT. Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol 2007; 14: 1229-36. http://dx.doi.org/10.1245/s10434-006-9111-z
38. NIKOFOROVA MN, KIMURA ET, GANDHI M, BIDDINGER PW, KNAUF JA et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endo and metabol 2003; 88: 5399-5404.
39. VAN CUSTEM E, KOHNE CH, LANG I, FOLPRECHT G, NOWACKI MP et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9. http://dx.doi.org/10.1200/JCO.2010.33.5091